unknown
Stage
About
Eveliqure Biotechnologies is an Austrian biotech developing live attenuated, orally delivered vaccines to prevent diarrhoeal diseases. Its lead candidate, ShigETEC, is designed to protect against Shigella and enterotoxigenic E. coli (ETEC) and is in Phase 2b clinical testing.
Explore Eveliqure Biotechnologies's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.